NMRA says letter circulated targeting Alaris Lanka products is fake

The National Medicines Regulatory Authority (NMRA) says a letter circulating on social media targeting local Healthcare and Pharmaceutical Corporation Alaris Lanka (Pvt) Ltd is fake.

The letter claiming to be issued by the NMRA had said a ban had been imposed on the importation of glutathione molecule combination products.

The forged letter further claimed that the ban had been applied to Facia Premium, which is one of the most popular products of Alaris Lanka, that has been in the healthcare and pharmaceutical industry since 2002.

It was addressed to Sri Lanka Customs Director General Maj. Gen. (Retd.) Vijitha Ravipriya, ordering the Customs to take necessary measures to confiscate all products containing the said molecule coming into the country.

According to The Morning, NMRA Chief Executive Officer (CEO) Dr. Kamal Jayasinghe clarified that the Authority has not imposed any such ban or made any such request from the Customs Department at present.

Commenting on the matter, Alaris Lanka Managing Director Tharanga Weerawardena said it is suspected that the letter may have been circulated by two of its competitors who had allegedly colluded to tarnish the company’s reputation.

Stating that a similar letter had been published in 2019 as well, Weerawardena added that the same letter has been republished with a change in the date. (NewsWire)

Video